Abstracts Archive - Page 557 of 2425 - ACR Meeting Abstracts

Abstract Number: 0068 • ACR Convergence 2021
Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Randomization Studies
Nicholas Harvey¹, Jose Garrido-Mesa², Zhixiu Li³, David Evans⁴, Peter Sternes⁵ and Matthew Brown², ¹Molecular Genetics, London, United Kingdom, ²King's College London, London, United Kingdom, ³Queensland University of Technology, Brisbane, Australia, ⁴University of Queensland, Brisbane, Australia, ⁵Queensland University of Technology, Bisbane, Australia
Background/Purpose: There is strong evidence from animal models, human microbiome profiling studies, genetic analyses, and from the model of reactive arthritis, that AS is caused…
Abstract Number: 0071 • ACR Convergence 2021
Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Gustavo Balbi¹, Yasaman Ahmadzadeh², Maria Tektonidou³, Vittorio Pengo⁴, Savino Sciascia⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul R Fortin⁹, Chary lopez-pedrera¹⁰, Lanlan Ji¹¹, Tatsuya Atsumi¹², Hannah Cohen¹³, Guilherme Ramires de Jesus¹⁴, D. Ware Branch¹⁵, Cecilia Nalli¹⁶, Nina Kello¹⁷, Michelle Petri¹⁸, Esther Rodriguez-Almaraz¹⁹, Giuseppe Barilaro²⁰, Jason Knight²¹, Bahar Artim-Esen²², Rohan Willis²³, Maria Laura Bertolaccini²⁴, Robert Roubey²⁵, Doruk Erkan², Danieli De Andrade¹ and on Behalf of APS ACTION², ¹University of São Paulo, São Paulo, Brazil, ²Hospital for Special Surgery, New York, NY, ³FORZAFORTE HELLAS LTD, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵University of Turin, Turin, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸University of Milan, Milan, Italy, ⁹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Hokkaido University, Sapporo, Japan, ¹³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah, Salt Lake City, UT, ¹⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁷Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Clínic Barcelona - Hospital Universitari, Barcelona, Spain, ²¹University of Michigan, Ann Arbor, MI, ²²Istanbul University School of Medicine, İstanbul, Turkey, ²³University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵University of North Carolina, Chapel Hill, NC
Background/Purpose: Damage Index in APS (DIAPS) is a scoring system developed to assess long-term damage in thrombotic primary antiphospholipid syndrome (PAPS), which also correlates with…
Abstract Number: 0074 • ACR Convergence 2021
Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19
David Yaich¹, Brandon Ptak¹, Emma Roellke¹, Erin Miller¹, Juliet Kim¹, Juan Gaztanaga¹, Wendy Drewes¹, James Ciancarelli², Jasmin Divers¹, Megan Winner¹, Amy Rapkiewicz¹ and Steven Carsons³, ¹NYU Langone Hospital - Long Island, Mineola, NY, ²NYU Hospital Hospital- Long Island, Mineola, NY, ³NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Critically ill patients with COVID-19 infection have a profound hypercoagulable state and can often develop thromboses in many different vascular beds. Given the presence…
Abstract Number: 0073 • ACR Convergence 2021
Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”)
Cecilia Chighizola¹, Francesca Pregnolato², Danieli De Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Paul R Fortin⁸, Tatsuya Atsumi⁹, Maria Efthymiou,¹⁰, Guilherme Ramires de Jesus¹¹, D. Ware Branch¹², Cecilia Nalli¹³, Michelle Petri¹⁴, Esther Rodriguez-Almaraz¹⁵, Ricard Cervera¹⁶, Yu Zuo¹⁷, Rohan Willis¹⁸, Elisa Bison¹⁹, Ian Mackie²⁰, Hannah Cohen²¹, Robert Roubey²², Doruk Erkan²³ and Maria Laura Bertolaccini²⁴, ¹University of Milan, Milan, Italy, ²Università degli Studi di Milano, Milan, Italy, ³University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Joint Rheumatology Program, Laiko Hospital, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸CHU de Quebec - Universite Laval, Québec City, QC, Canada, ⁹Hokkaido University, Sapporo, Japan, ¹⁰Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ¹¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹²University of Utah, Salt Lake City, UT, ¹³ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Hospital Clinic Barcelona, Barcelona, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Texas Medical Branch, Galveston, TX, ¹⁹University of Padova, Padova, Italy, ²⁰University College London, London, United Kingdom, ²¹Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ²²UNC, Chapel Hill, NC, ²³Hospital for Special Surgery, New York, NY, ²⁴King's College London, London, United Kingdom
Background/Purpose: Data on fluctuation of antibodies against domain 1 (anti-D1) of β2-glycoprotein I (β2GPI) are scarce. Patients with antiphospholipid syndrome (APS) and all three criteria…
Abstract Number: 0072 • ACR Convergence 2021
Immunosuppression Use in Primary Antiphospholipid Antibody Positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Rebecca Karp- Leaf², Danieli Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Savino Sciascia⁶, Amaia Ugarte⁷, H. Michael Belmont⁸, Maria Gerosa⁹, Paul R Fortin¹⁰, Chary lopez-pedrera¹¹, Lanlan Ji¹², Tatsuya Atsumi¹³, Hannah Cohen¹⁴, Guilherme Ramires de Jesus¹⁵, D. Ware Branch¹⁶, Cecilia Nalli¹⁷, Nina Kello¹⁸, Michelle Petri¹⁹, Esther Rodriguez-Almaraz²⁰, Ricard Cervera²¹, Jason Knight²², Bahar Artim-Esen²³, Rohan Willis²⁴, Maria Laura Bertolaccini²⁵, Robert Roubey²⁶, Doruk Erkan¹ and on Behalf of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Boston, MA, ³Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴FORZAFORTE HELLAS LTD, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶University of Turin, Turin, Italy, ⁷Hospital Universitario Cruces, Barakaldo, Spain, ⁸NYU School of Medicine, New York, NY, ⁹University of Milan, Milan, Italy, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹¹IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹²Peking University First Hospital, Beijing, China (People's Republic), ¹³Hokkaido University, Sapporo, Japan, ¹⁴Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶University of Utah, Salt Lake City, UT, ¹⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁸Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Clinic Barcelona, Barcelona, Spain, ²²University of Michigan, Ann Arbor, MI, ²³Istanbul University School of Medicine, İstanbul, Turkey, ²⁴University of Texas Medical Branch, Galveston, TX, ²⁵King's College London, London, United Kingdom, ²⁶University of North Carolina, Chapel Hill, NC
Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…
Abstract Number: 0067 • ACR Convergence 2021
Mendelian Randomisation Analysis of Protein Quantitative Trait Loci with Ankylosing Spondylitis Reveals Causative Involvement of Key Effector Proteins and Pathways
Nicholas Harvey¹, Zhixiu Li², Jose Garrido-Mesa³, Jie Zheng⁴, Paul Wordsworth⁵, John Reveille⁶, Mario Falchi³, Niccolo Rossi³, Alessia Visconti³, David Evans⁷ and Matthew Brown³, ¹Molecular Genetics, London, United Kingdom, ²Queensland University of Technology, Brisbane, Australia, ³King's College London, London, United Kingdom, ⁴Bristol University, Bristol, United Kingdom, ⁵Oxford University, Oxford, United Kingdom, ⁶Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁷University of Queensland, Brisbane, Australia
Background/Purpose: Susceptibility to ankylosing spondylitis (AS) is known to be highly influenced by genetic factors, with heritability assessed in twins of >90%, with >115 genetic…
Abstract Number: 0078 • ACR Convergence 2021
Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
Jinan al-naqeeb¹, Gaobin Bao², Cristina Drenkard² and S Sam Lim³, ¹Emory University, Decatur, GA, ²Emory University, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Although APS was originally described in those with SLE, the epidemiology and clinical characteristics of secondary APS (2APS) has not been well described in…
Abstract Number: 0077 • ACR Convergence 2021
Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus
Prarthana Jain, Jim Oates, Dulaney Wilson and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Antiphospholipid antibody (aPL) positivity is associated with elevated risk of thrombosis among patients with SLE, but other clinical associations are less well-known. The goal…
Abstract Number: 0075 • ACR Convergence 2021
Endothelial Cell-activating Antibodies in COVID-19
Hui Shi¹, Yu Zuo², Sherwin Navaz², Alyssa Harbaugh², Claire Hoy², Alex Gandhi², Gautam Sule², Srilakshmi Yalavarthi², Kelsey Gockman², Jacqueline Madison², Jintao Wang², Melanie zuo², Yue Shi³, Michael Maile², Yogendra Kanthi² and Jason Knight², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Shanghai Sports School, Shanghai, China (People's Republic)
Background/Purpose: Patients with COVID-19 are at high risk for occlusion of vascular beds of all sizes. Considering endothelial cell activation has regularly been described as…
Abstract Number: 0079 • ACR Convergence 2021
Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study
Daniele Lini¹, Cecilia Nalli², Laura Andreoli³, Francesca Crisafulli¹, Micaela Fredi¹, Maria Grazia Lazzaroni¹, Viktoria Bitsadze⁴, Antonia Calligaro⁵, Valentina Canti⁶, Roberto Caporali⁷, Francesco Carubbi⁸, Cecilia Chighizola⁹, Paola Conigliaro¹⁰, Fabrizio Conti¹¹, Caterina De Carolis¹², Teresa Del Ross⁵, Maria Favaro⁵, Maria Gerosa⁹, Annamaria Iuliano¹³, Jamilya Khizroeva⁴, Alexander Makatsariya⁴, Pier Luigi Meroni¹⁴, Marta Mosca¹⁵, Melissa Padovan¹⁶, Roberto Perricone¹⁰, Patrizia Rovere Querini⁶, Gian Domenico Sebastiani¹³, Chiara Tani¹⁷, Marta Tonello¹⁸, Simona Truglia¹¹, Dina Zucchi¹⁵, Franco Franceschini¹ and Angela Tincani¹⁹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ³University of Brescia, Brescia, Italy, ⁴Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, ⁵Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, ⁶Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁷Policlinico S. Matteo University, Pavia, Italy, ⁸Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, ⁹University of Milan, Milan, Italy, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, ¹¹Lupus Clinic, Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Rome, Italy, ¹²Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, ¹³Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, ¹⁴Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, ¹⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁶Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy, ¹⁷Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁸BSC, Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, ¹⁹ASST Spedali Civili-University of Brescia, Gussago, Italy
Background/Purpose: APS is a rare autoimmune disease characterized by thrombotic events and/or pregnancy morbidities in the presence of confirmed positivity for aPL. Complement was demonstrated…
Abstract Number: 0081 • ACR Convergence 2021
Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
Massimo Radin¹, Alice Barinotti¹, Irene Cecchi², Silvia Grazietta Foddai¹, Elena Rubini¹, Dario Roccatello¹, Elisa Menegatti¹ and Savino Sciascia¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Risk stratification in patients with antiphospholipid antibodies (aPL) remains a clinical challenge. We aim to evaluate the role of Thrombin Generation Assay (TGA) in…
Abstract Number: 0080 • ACR Convergence 2021
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Pedro Gaspar¹, Filipa Farinha², Zara Sayar³, Maria Efthymiou,⁴, Hannah Cohen³ and David Isenberg², ¹Department of Internal Medicine 2, University Hospital of Santa Maria, Lisbon, Portugal, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom
Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…
Abstract Number: 0076 • ACR Convergence 2021
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
Abstract Number: 0070 • ACR Convergence 2021
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Ecem Sevim², Guilherme Ramires de Jesus³, Ricard Cervera⁴, Lanlan Ji⁵, Vittorio Pengo⁶, Amaia Ugarte⁷, Danieli Andrade⁸, Laura Andreoli⁹, Tatsuya Atsumi¹⁰, Paul R Fortin¹¹, Maria Gerosa¹², Yu Zuo¹³, Michelle Petri¹⁴, Savino Sciascia¹⁵, Maria Tektonidou¹⁶, Maria Angeles Aguirre¹⁷, D. Ware Branch¹⁸, Doruk Erkan¹ and on Behalf of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Montefiore Medical Center - Wakefield Campus, Bronx, NY, ³Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Peking University First Hospital, Beijing, China (People's Republic), ⁶Padova University Hospital, Padova, Italy, ⁷Hospital Universitario Cruces, Barakaldo, Spain, ⁸Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹University of Brescia, Brescia, Italy, ¹⁰Hokkaido University, Sapporo, Japan, ¹¹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹²University of Milan, Milan, Italy, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵University of Turin, Turin, Italy, ¹⁶FORZAFORTE HELLAS LTD, Athens, Greece, ¹⁷IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹⁸University of Utah, Salt Lake City, UT
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…
Abstract Number: 0051 • ACR Convergence 2021
Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid
Jacqueline Lai¹, Sara Rahmati², Raam Sivakumar², Katerina Oikonomopoulou³, Fatima Abji⁴ and Vinod Chandran⁵, ¹McMaster University, Hamilton, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that currently lacks diagnostic biomarkers. We hypothesized that there are differences in the protein intensities in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].